4 results about "Cell cycle progression" patented technology

The application discloses application of PGD2 in promoting rumen development of young ruminants, and application of PGD2 in young ruminants promotes proliferation and differentiation of rumen wall cells, and further promotes rumen development and improves the digestive and absorptive capacity of the rumen. 2+ It is found that PGD2 can promote rumen development by activating Ca signal pathways, promoting expression of CAMK2A protein, promoting cell cycle progression, promoting rumen development, and ensuring animal health. Therefore, PGD2 can be used for preparing a medicine for promoting rumen development of young ruminants.

This invention discloses a monoclonal antibody targeting NECTIN4, its associated nucleic acid, vector, host cell, and its application in the preparation of antitumor drugs, belonging to the field of biomedical technology. The monoclonal antibody comprises a specific heavy chain variable region VH and a light chain variable region VL. The HCDR1-3 amino acid sequences of VH are shown in SEQ ID NO:1-3, and the LCDR1-3 amino acid sequences of VL are shown in SEQ ID NO:4-6. This invention also provides the nucleic acid encoding the antibody (SEQ ID NO:10), a vector containing the nucleic acid, and a host cell containing the nucleic acid or the vector. This Nectin4 monoclonal antibody can specifically target and bind to the NECTIN4 protein on the surface of tumor cells, inhibiting tumor cell cycle progression, proliferation, migration, and invasion by regulating the NF-κB pathway. As a naked antibody, it exhibits significant tumor-targeting inhibitory effects, especially for esophageal cancer, and can also be used for targeted therapy of other malignant tumors such as breast cancer and lung cancer. This monoclonal antibody has a better safety profile than ADC drugs, providing a new option for tumor targeted therapy.

The application belongs to the technical field of pharmaceutical chemistry, and particularly relates to application of 1-pentyl-tetradecahydro-1H-cyclopenta[1,2-a]phenanthrene in treatment of acute myeloid leukemia. The application provides 1-pentyl-tetradecahydro-1H-cyclopenta[1,2-a]phenanthrene compounds with a novel skeleton. Experimental verification shows that the compounds have excellent inhibitory activity on AML cancer cells, and the mechanism is clear: the compounds can directly inhibit the activity of AML cancer cells, inhibit the proliferation of cancer cells by blocking the cell cycle process, and can specifically induce AML cancer cell apoptosis, thereby realizing the AML treatment effect. The application provides a new active compound candidate for the targeted treatment of acute myeloid leukemia, and lays an important foundation for the research and development of related drugs.

This invention relates to the field of biomedical technology, and more particularly to the use of a combination of RVX208 and temozolomide for the treatment of glioblastoma. It also relates to the use of RVX208 to resensitize temozolomide-resistant cancers to temozolomide treatment. The use of at least one of RVX208, a pharmaceutically acceptable salt of RVX208, a solvate of RVX208, a hydrate of RVX208, a polymorph of RVX208, an isomer of RVX208, a prodrug form of RVX208, and temozolomide in the preparation of a glioblastoma therapeutic agent. RVX208 inhibits the transcriptional activity of various genes related to cell cycle progression and proliferation maintenance by inhibiting BET family proteins or other target molecules, leading to cell cycle arrest, inhibition of cell proliferation, and induction of programmed cell death. RVX208 also interferes with the transcriptional expression of genes related to mitochondrial homeostasis regulation, resulting in a decrease in mitochondrial membrane potential and reduced ATP production, thus enabling RVX208 to disrupt mitochondrial function in GBM cells and produce a synergistic antitumor effect with temozolomide.